Limits...
Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z - Cancer Sci. (2014)

Bottom Line: We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines.A significantly poorer treatment outcome (P < 0.05) was found in the low-expression group and verified in the validation cohort (76 cases, P < 0.05).Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Major Diseases in Children (Capital Medical University), Ministry of Education, National Key Discipline of Pediatrics, Ministry of Education, Hematology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Show MeSH

Related in: MedlinePlus

The receiver operating characteristic (ROC) curve of miR-210 expression to predict relapse and induction failure in the test cohort (38 patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317805&req=5

fig01: The receiver operating characteristic (ROC) curve of miR-210 expression to predict relapse and induction failure in the test cohort (38 patients).

Mentions: Good prognostic significance of miR-210 expression for relapse at any site and induction failure was shown by ROC curve analysis in the test cohort (38 cases) (Fig. 1, AUC = 0.871, P = 0.001). The optimal cut-off value of miR-210 expression identified by ROC curve analysis was 3.8243 and had acceptable sensitivity and specificity (0.700 and 0.750, respectively). Using this cut-off value, the test cohort was separated into low-expression and high-expression groups (15 and 23 cases, respectively). The incidence of relapse or induction failure was significantly higher (40 vs 8.6%, respectively; P = 0.039), and the 5-year LFS (log-rank: P = 0.017; Fig. 2a), EFS (log-rank: P = 0.017; Fig. 2b) and OS (log-rank: P = 0.016; Fig. 2c) were significantly poorer in the low-expression group.


Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X, Liu F, Wu M, Deng G, Ding W, Jia H, Li Z - Cancer Sci. (2014)

The receiver operating characteristic (ROC) curve of miR-210 expression to predict relapse and induction failure in the test cohort (38 patients).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317805&req=5

fig01: The receiver operating characteristic (ROC) curve of miR-210 expression to predict relapse and induction failure in the test cohort (38 patients).
Mentions: Good prognostic significance of miR-210 expression for relapse at any site and induction failure was shown by ROC curve analysis in the test cohort (38 cases) (Fig. 1, AUC = 0.871, P = 0.001). The optimal cut-off value of miR-210 expression identified by ROC curve analysis was 3.8243 and had acceptable sensitivity and specificity (0.700 and 0.750, respectively). Using this cut-off value, the test cohort was separated into low-expression and high-expression groups (15 and 23 cases, respectively). The incidence of relapse or induction failure was significantly higher (40 vs 8.6%, respectively; P = 0.039), and the 5-year LFS (log-rank: P = 0.017; Fig. 2a), EFS (log-rank: P = 0.017; Fig. 2b) and OS (log-rank: P = 0.016; Fig. 2c) were significantly poorer in the low-expression group.

Bottom Line: We further examined its effect on the response to chemotherapeutic drugs in the Reh and RS4;11 cell lines.A significantly poorer treatment outcome (P < 0.05) was found in the low-expression group and verified in the validation cohort (76 cases, P < 0.05).Increasing/decreasing miR-210 expression using agomir/antagomir could enhance or reduce the response of Reh cells and RS4;11 cells to daunorubicin/dexamethasone/L-asparaginase and daunorubicin/dexamethasone/vincristine, respectively.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Major Diseases in Children (Capital Medical University), Ministry of Education, National Key Discipline of Pediatrics, Ministry of Education, Hematology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Show MeSH
Related in: MedlinePlus